You just read:

Uptake of Merck KGaA's Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals

News provided by

Spherix Global Insights

Mar 27, 2018, 04:00 ET